CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer
Friday, May 15, 2026 1 min read
Key Takeaway: The article discusses the potential of CAR T cells targeting pan-Tumor antigens MICA/B in combination with standard of care treatments. It highlights the unique approach of utilizing these therapies without conditioning chemotherapy, suggesting a broad application in cancer treatment. However, specific details on efficacy or clinical outcomes are not provided.
Price reaction · baseline $1.9 (2026-05-14 close) · hit pre-market · 3 other FATE headline(s) in the window, move may be shared
day 0 close
-7.6%
day 1 · peak
-8.9%
day 3
-3.2%
Market Sentiment Analysis
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.